Docket No.: 0701.196A IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Addressed to Jerussi et al. 2834 Applicant(s): Confirmation No.: Commissioner for Patents Serial No.: 10/663,173 Group Art Unit: 1614 P.O. Box 1450 Filed: 09/16/2003 To Be Assigned Alexandria, VA 22313-1450 Examiner: TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-Title: DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE

AND ITS FORMAMIDE

# INFORMATION DISCLOSURE STATEMENT

Dear Sir: This Information Disclosure Statement is submitted together with the application being filed herein; or is submitted for the first time; or submitted as a Supplemental Information Disclosure Statement in addition to an Information Disclosure Statement filed together with the application on September 16, 2003, and such submission is being made: under 37 CFR 1.97(b), within three months of filing national application or date of entry of international application, or before mailing date of first office action on the merits, whichever occurs last; or under 37 CFR 1.97(c) together with either a: Statement under 37 CFR 1.97(e), or a \$180.00 fee under 37 CFR 1.17(p), after the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first; or under 37 CFR 1.97(d), filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee, together with a: Statement under 37 CFR 1.97(e), and a \$180.00 fee set forth in 37 CFR 1.17(p); and, furthermore, it is being submitted to disclose results of an International Search Report received in a related PCT application, Serial No. PCT/US03/29110 filed on September 16, 2003.

Applicant(s) submit herewith Information Disclosure Citation form listing patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56, together with any required copies of references.

It is requested that the information disclosed herein be made of record in this application.

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Date of Deposit: March 29, 2004

EDWARD TIMMER

Respectfully submitted,

EDWARD TIMMER

Attorney for Applicant(s)

Registration No. 46,248

Dated: March 29, 2004

HESLIN ROTHENBERG FARLEY & MESITI, P.C.

5 Columbia Circle

Albany, New York 12203

Telephone:

(518) 452-5600

Facsimile:

(518) 452-5579

# SUPPLEMENTAL INFORMATION SUPPLEMENTAL INFORMATION Inventors: Jerussi et al. Filing Date: 09/16/2003 GAU: 1614

## UNITED STATES PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
			•			

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Int' Class	Int'l Subclass	Translation				
							Yes	No			
	-		ļ			· · · · · · · · · · · · · · · · · · ·					
•				THER DOCUN		ges, Etc.)		<b>-</b>			
	CG	Deninno, Michael P.; Eller, C; Etienne J B: "The preparation and intra-and intermocular addition reactions of acylic n-acylimines: Application to the synthesis of (+-) sertraline" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 66, 2001, pages 6988-6993, XP002902612, ISSN: 0022-3263; scheme 4, page 6992.									
	СН			G. NEURO-PS XP002270139 a		ARMACOL.	BIOL. PSYO	CHIAT., vol			
	CI			Shuyen: "Com York, XP00227			nthetic Meth	ods" 1971,			
EXAMINER:				Date Considered:							

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.